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Abstract Peak sales are an important metric in the pharmaceutical industry.
Specifically, managers are focused on the height-of-peak-sales and the time required
achieving peak sales. We analyze how order of entry and quality affect the level of
peak sales and the time-to-peak-sales of pharmaceutical brands. We develop a
growth model that includes these two variables as well as control variables for own
and competitive marketing activities. We find that early entrants achieve peak sales
later, and they have higher peak-sales levels. High-quality brands achieve peak sales
earlier, and their peak-sales levels are higher. In addition, quality has a moderating
effect on the order of entry effect on time-to-peak-sales. Our results indicate that late
entrants have longer expected time-to-peak-sales when they introduce a brand with
high quality.
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1 Introduction
New products play a very important role in the pharmaceutical industry (Leenders
and Wierenga 2008; Stremersch and van Dyck 2009). Pharmaceutical firms
constantly introduce new drugs, and for these new drugs, peak sales represent an
important metric, frequently used by investors to assess pharmaceutical firms’ value
(Obeid and Vine 2005; Suresh et al. 2006).
Peak sales can be characterized along two dimensions: the height-of-peak-sales
and the time-to-peak-sales. Both metrics are closely related to new product
performance such as cumulative sales. Intuitively, a brand with a higher level of
peak sales is likely to have higher average sales over its life cycle. As a result,
cumulative sales are also higher. Similarly, a brand with longer time-to-peak-sales
enjoys a longer period of growth that contributes to accumulate sales and achieve a
higher level of peak sales. Consequently, cumulative sales are again higher.
There are, however, exceptions to these rules. For example, a high level of peak
sales may be achieved very fast. Although, we cannot rule out such a case
theoretically, we do not believe it occurs often in reality because of restrictions to
growth. Note that the growth rate needs to double if the same level of peak sales is to
be achieved in half of the time. Firms can handle faster growth only up to a certain
level due to supply and resource restrictions. In Appendix A, we also demonstrate
that faster growth implies a higher variance of sales and therefore higher cash-flow
volatility which is not desirable (Srivastava et al. 1998). Hence, even if demand
might allow for a shorter time-to-peak sales, there are limits to growth from the
supply side. The broad sample of new drugs that forms the basis of our empirical
study supports our view. Time-to-peak-sales enhances height-of-peak sales and both
peak-sales metrics increase cumulative brand sales. Together the two metrics explain
more than 96% of observed variance in cumulative brand sales.
Time-to-peak-sales and height-of-peak-sales provide two important yardsticks
that are easy to evaluate and predict even before launch. Assume management
wants to assess the sales potential of a new product two years prior to launch.
Cumulative sales may be obtained from the life cycle curve. Predicting the lifetime
and sales for all periods, however, requires much more information than predicting
only two peak-sales metrics. It is much easier to reach a consensus estimate for
time-to-peak-sales and height-of-peak-sales. For pharmaceuticals, as an example,
management can triangle information on the population size, the incidence of a
disease and the reachable market share for the new drug to obtain an estimate for
the height-of-peak-sales. Management would certainly use information on
competitive entries, order of entry, marketing investment, etc. to predict the
peak-sales metrics. Our empirical analysis provides important insights into the
relevance of these variables for peak sales. Importantly, the analysis also suggests
that those variables do not provide explanatory power for cumulative sales beyond
the two peak-sales metrics. Hence, peak-sales metrics cannot simply be substituted
by other predictors.
It is therefore not surprising that peak-sales metrics are widely adopted in
practice, especially within the pharmaceutical industry. For example, Salix
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Pharmaceuticals reportedly has tumbled because its IBD franchise will “only achieve
peak sales of $ 99 million, lower than its previous estimate of $ 135 million because
of the Dec. 28 approval of three generic balsalazide (Colazal) formulations by the
Food and Drug Administration” (Trading Markets.Com 2007). The importance of
peak-sales metrics prompts business intelligence agencies such as IMS or Data-
monitor to predict the peak sales of newly introduced drugs (e.g., Datamonitor
2007). Not only are the metrics important in practice (Obeid and Vine 2005), but
scholars also acknowledge their relevance. For example, Bauer and Fischer (2000)
and Schmid and Smith (2002) demonstrate that time-to- and height-of-peak-sales
differ across brands introduced into different drug categories and countries due to
factors such as order of entry.
In the marketing literature, there has been extensive attention to the role of order
of entry and quality with regard to (new product) performance (Gielens and
Dekimpe 2001; Kalyanaram and Urban 1992; Kalyanaraman and Wittink 1994;
Robinson and Fornell 1985; Shankar et al. 1998). An important debate addresses the
question whether first movers really have a competitive advantage as is often
attributed to them (Golder and Tellis 1993; Kornelis et al. 2008; Zhang and
Narasimhan 2000). Quite in contrast, recently Tellis and Johnson (2007) argue that
delivering superior quality is considered as the most important driver of new product
success. Hence, we assess the role of order of entry and quality for the market
performance of a new drug in terms of peak sales.
The main objective of this study is to determine the drivers of height-of peak-
sales and time-to-peak-sales in the pharmaceutical industry. Through this study we
contribute to the literature on new products and brand life cycles (Hauser et al.
2006), as this is the first study to investigate drivers of time-to- and height-of-peak-
sales. We show that some drivers differentially impact height-of-peak-sales and time-
to-peak-sales. For example, marketing expenditures increase the level of peak sales,
while they decrease the time-to-peak-sales. We aim to contribute to the literature on
drivers of new product performance with a further investigation on the relative roles
of order of entry, quality, and marketing efforts (see Tellis and Johnson 2007).
Importantly, our results suggest that quality has by far the strongest positive effect on
height-of-peak-sales, while it reduces the time-to-peak-sales. Finally, by executing
this study in the pharmaceutical industry we also contribute to existing knowledge
on pharmaceutical marketing (e.g. Kremer et al. 2008; Stremersch and van Dyck
2009).
The article is organized as follows: In the next section, we review the literature on
drug life cycles and provide explanations why peak sales is a quite common
phenomenon in the evolution of drug sales. Subsequently, we discuss potential
drivers of time-to- and height-of-peak-sales and how they might affect the two
metrics. We develop a model to measure the effects, then describe data from the
pharmaceutical industry and discuss estimation issues. We follow up with a
discussion of the empirical results. We continue with a cross-sectional analysis of
new product performance to substantiate the relevance of the suggested metrics. In
the final section, we conclude with research implications, limitations, and
suggestions for further research.
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2 Drug life cycles and peak sales
2.1 Life cycle research
Studying the length and the shape of brand life cycles has a long history, including
studies by Bauer and Fischer (2000), Brockhoff (1967), and Polli and Cook (1969).
Research on specific metrics at the brand level in the development of the brand life
cycle is scarce. Height-of-peak-sales and time-to-peak-sales have not been studied so
far. Remarkably, studying the diffusion of article citations in Econometrica and the
Journal of Econometrics, Fok and Franses (2007) model the time-to-peak citations
and peak-citations of an article. Hence, though studied in a different context, there is
academic attention for peak metrics in the econometric diffusion literature. We
believe it is important to study such metrics in a new product context as well, as we
will show that both these metrics are highly relevant for practice and they both are
the most important determinants of cumulative brand sales.
Research at the product level has, however, investigated other specific
metrics, as overviewed in Table 1. Several studies consider time-to-takeoff and
subsequent growth of consumer durables (i.e., VCRs, televisions), as well as their
drivers (Agarwal and Bayus 2002; Neelameghan and Chintagunta 2004; Golder
and Tellis 1997; Stremersch and Tellis 2004; Tellis et al. 2003). Bayus (1998)
specifically analyzes product lifetime as an important metric. Although these
studies provide insights into which factors (i.e., economic, cultural) influence time-
to-takeoff at the product level by country, they do not clarify the drivers at the
brand level.
2.2 Brand life cycles in drugs
The development of demand for a new drug derives from both adoptions and
repeats. For many drugs, the evolution of sales shows a peak. In Fig. 1, we depict the
sales development of different brands in the French calcium channel blockers
market. On the X-axis, we display the launch years of new drugs, and on the Y-axis,
we provide annual sales for three entrants in this market. The figure clearly shows
the occurrence of sales peaks. For example, the second entrant reaches its peak in
1988 with a sales level of approximately 200 million daily dosages.
The theories of adoption and imitation (Bass 1969) and informational cascades
(Golder and Tellis 2004) explain why brand sales follows a life cycle. However, they
are usually associated with the product level and first-time adoptions. Brand sales
are, in addition, composed of repeat purchases, and they are subject to competition
(Hahn et al. 1994).
Although some authors have questioned the transfer of the product life cycle
concept to brands (Dhalla and Yuspeh 1976), brand life cycles have been reported
quite frequently. The broadest evidence for brand life cycles is available for
pharmaceuticals. Bauer and Fischer (2000), Corstjens et al. (2005), Cox (1967),
Grabowski and Vernon (1990), Hahn et al. (1994), Lilien et al. (1981), Rao and
Masataka (1988), and Simon (1979) all find strong evidence for the existence of a
drug life cycle. In total, these researchers document the life cycles for more than 500
newly introduced drugs.
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Table 1 Overview of prior studies investigating specific metrics over a brand’s/product’s life cycle
Study Metrics Data Antecedents Major findings
Golder and
Tellis
(1997)
Time-to-
takeoff
Aggregated sales by
category in the
U.S.
Price, year of introduction,
market penetration
- Average time-to-takeoff is
six years.
- At takeoff, price is 63% of
introductory price, and
penetration is 1.7%.
- Time-to-takeoff decreases
after World War II.
Bayus
(1998)
Product
lifetime
Aggregated sales at
various product
market levels in the
U.S. PC industry
Product introduction year,
firm entry year,
technology substitution
- Product life cycles are not
shrinking over time.
- Observed acceleration in
life cycles is a result of
technology substitution.
Tellis et al.
(2003)
Time-to-
takeoff
Aggregated sales by
category for
different European
countries
Economic and cultural
variables
- Time-to-takeoff varies sub-
stantially across European
countries.
- Culture partially explains
country differences.
- Advantages for waterfall
strategy for international
product introduction.
Agarwal
and
Bayus
(2002)
Time-to-
takeoff
Aggregated sales by
category in the U.S.
Price, new firm entry,
commercialization year
- Takeoff in new firm entry
leads to sales takeoff.
- Firm entry dominates other
drivers of time-to-takeoff.
Stremersch
and
Tellis
(2004)
Rate of
growth,
duration of
growth
Aggregated sales by
category for
different European
countries
Economic and cultural
variables
- Growth metrics vary
substantially across
European countries.
- Economic factors primarily
explain country
differences.
Golder and
Tellis
(2004)
Time-to-
takeoff,
slowdown,
duration of
growth
Aggregated sales by
category in the U.S.
Price, economic growth,
type of product, market
penetration
- Slowdown occurs when
sales declines by about
15%.
- Probability of slowdown is
higher when economic
growth is slower, price
reductions are smaller, and
penetration is higher.
- Leisure-enhancing products
tend to have higher growth
rates and shorter growth
stages.
This Study Time-to-
peak-sales,
height-of-
peak-sales
Brand sales of 45
pharmaceutical
brands in France,
Germany, Italy, and
UK
Own marketing
expenditures, competitive
marketing expenditures,
order-of-entry, quality,
number of
competitors
- Order of entry reduces time-
to-peak-sales and height-
of-peak-sales.
- Quality reduces time-to-
peak-sales and increases
height-of peak sales.
- A higher quality reduces the
negative effect of order of
entry on time-to-peak-sales.
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There are potentially several reasons why especially pharmaceuticals exhibit a
peak in their sales trajectory. First, diffusion dynamics seem to be dominant for the
evolution of (prescription) drug sales. Although refills have a large share in total
drug sales, sales dynamics are predominantly driven by first-time prescriptions. This
is simply due to the fact that physicians are reluctant to change a drug (i.e. the first-
time prescription) once it has been found to work for a patient, even in response to
heavy marketing initiatives by competitor brands. As a result, researchers have
adopted diffusion approaches to model drug sales with repeats where repeat rates are
assumed constant (e.g., Hahn et al. 1994; Shankar et al. 1998). Second,
pharmaceutical companies concentrate the bulk of their marketing efforts (i.e.,
detailing) on the first two years after launch, which causes an immediate strong
increase in prescriptions but results in slower sales growth or even decline in later
years when marketing support is only limited (Osinga et al. 2010). Third, by
definition there is a limit in users of a drug as it is only relevant for patients with a
specific treatment for a disease. Fourth, the entry of new competitors may inhibit
sales growth to continue. These competitors may be other innovative drugs within
the same or new categories, or generics after the patent has expired.
One might argue that instead of studying time-to- and height-of-peak-sales, one
should study the time-to-takeoff metric (e.g. Tellis et al. 2003). As noted, this metric
has been studied at the category level but not at the brand level. So far, there is no
empirical evidence in the literature that this phenomenon occurs at the brand level,
as well. We explored the available brand time-series but did not find evidence for a
sales-takeoff phenomenon. Hence, beyond our substantive arguments there are also
empirical arguments to study peak-sales metrics.
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Fig. 1 Illustration of peak sales
in the French market for
calcium channel blockers
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3 Variables affecting peak sales of pharmaceutical brands
3.1 Potential peak-sales drivers
In this study, we focus on the impact of order of entry and quality on (1) the time-to-
peak-sales and (2) the height-of-peak-sales. We control for the effect of other,
potentially relevant variables. Specifically, we consider own and competitive
marketing support, the number of competitive entries into the market, the price of
the drug, and marketing expenditures by co-marketing partners as control variables
in the proposed brand sales model.
We define a pharmaceutical brand as a new chemical entity (NCE) marketed by a
company in a specific country. Typically, innovative drugs enjoy patent protection
for several years after launch. The competitive situation changes dramatically for an
innovative drug when its patent expires and cheaper generic competitors rush into
the market. In addition, innovative brands may be attacked by brands from other
categories that offer alternative forms of drug treatment (technological substitution).
Given that our data come from two categories that belong to the most innovative
categories without generic price competition in our observation period, we focus on
effects from competition among innovative prescription drugs within a category.
The sales evolution, and thus our focal metrics time-to-peak-sales and height-of-
peak-sales, is determined by four key metrics: the speed of adoption, the size of the
adopter (patient) potential, the repurchase (refill) rate and the interpurchase time. For
the majority of categories, repeat sales dynamics (interpurchase time and repurchase/
refill rate) are determined by exogenous factors such as therapy guidelines, patient
characteristics, and physician skills. Physicians rarely risk switching the patient to
another drug in response to marketing activities, because effectiveness and
compatibility of the new drug are uncertain to a patient. Additionally, the time
between refills follows medical needs for optimal treatment. As a consequence, we
focus on the diffusion metrics speed of adoption and size of adopter potential in our
discussion of order-of-entry and quality effects on peak sales as these decision
variables do not change the repeat sales dynamics. Aggregate repeat sales metrics are
constant over the life cycle of a drug unless therapy guidelines are replaced or the
distributions of patient and physician characteristics change systematically (Hahn et
al. 1994).
3.2 Effects of order of entry and quality
3.2.1 Order of entry
Multiple studies investigate the impact of order of entry on a brand’s market share
and sales (e.g., Kalyanaram et al. 1995; Robinson and Fornell 1985; Urban et al.
1986). Late entrants grow faster but achieve lower market share levels (Kalyanaram
and Urban 1992). The effect has also been demonstrated for pharmaceuticals (Berndt
et al. 1995; Shankar et al. 1998). These results are due to the fact that late-mover
drugs face a lower adopter potential that is faster penetrated. In addition, late entrants
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are less effective than early entrants in competing for the remaining potential adopters
(Kalyanaram and Urban 1992; Lieberman and Montgomery 1988). As a result, late
entrants expect a lower level of peak sales and a shorter time-to-peak-sales. We note,
however, that this effect may be moderated by other variables such as quality.
If late entrants penetrate the expected lower adopter potential at the same speed with
similar support and quality as earlier entrants, time-to-peak-sales will be shorter. There
are, however, good reasons to believe that their adoption speed is even faster than for
early entrants. This is because buying resistance at the category level is much lower than
it had been in earlier periods of the market life cycle. With more brands, consumers have
had multiple opportunities to collect consumption experiences. Furthermore, social
pressures on later adopters may favor trial probabilities for late mover brands (Bass
1969; Rogers 1995). The entry of another brand should not only increase brand variety
but also enhance marketing activity in terms of pricing, advertising and promotion,
which may lead to faster adoptions (Horsky and Simon 1983; Krishnan et al. 2000;
Prins and Verhoef 2007). To summarize, we expect order of entry to reduce both the
time-to-peak-sales and the height-of-peak-sales.
3.2.2 Quality
Quality is considered of essential importance for new product success (Tellis and
Johnson 2007). There is no doubt that a better quality increases the attractiveness of
the brand, which in turn should enlarge its adopter potential. Indeed, many studies
demonstrate the positive sales effect of quality for drugs (Berndt et al. 1995). Hence,
we expect a positive relation between the level of quality and the level of peak sales.
Adoption theory predicts that adoption will be faster for products with a relative
quality advantage (Rogers 1995). Consequently, high-quality brands should face
lower adoption barriers leading to a shorter time-to-peak-sales. The expected time-
to-peak-sales should therefore decrease with quality. However, we have also argued
that a better quality enlarges the adopter potential leading to a potentially longer
time-to-peak-sales. If this effect is stronger than the accelerated adoption (trial)
effect, we would expect a longer time-to-peak-sales for high-quality brands. As a
consequence, we cannot provide a clear prediction about the direction of the (direct)
quality effect and consider it as an empirical issue.
3.2.3 Interaction between order of entry and quality
Prior research has shown that the innovativeness of a new drug can reduce the
disadvantage from being a late entrant (Shankar et al. 1998). The study of Shankar et
al., however, focused on market share or brand sales, but not on peak-sales metrics.
Hence, we cannot make any inference about the interaction effect between quality
and order-of-entry with respect to the time-to-peak-sales. For time-to-peak-sales, we
expect that a higher quality reduces the negative effect of a late entry on the time-to-
peak-sales. A product with better quality may provide the late entrant with more
opportunities to gain prescriptions from competing incumbent brands. Low-quality
late entrants won’t be able to attract these prescriptions. As a consequence, the
adopter potential for low-quality entrants will be lower and they achieve their peak-
sales earlier than high-quality late entrants. Quality thus reduces the negative impact
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of order of entry on time-to-peak-sales, i.e. we expect a positive interaction effect
between quality and order of entry.
3.3 Control variables
3.3.1 Own marketing support
The amount of marketing support will affect the time-to- and height-of-peak-sales.
Prior research shows that higher marketing expenditures speed up adoption
(Gielens and Steenkamp 2007; Prins and Verhoef 2007; Steenkamp and Gielens
2003). Diffusion research demonstrates that higher marketing expenditures
increase the diffusion rate and extend the market potential of adopters (Horsky
and Simon 1983; Mahajan et al. 1990). Depending on which of these two effects is
larger, the time-to-peak-sales will be shortened or extended. A recent meta-analysis
(Kremer et al. 2008) shows that own marketing expenditures improve the sales
base of a drug. Hence, we expect a positive effect of own marketing support on the
height-of-peak-sales.
3.3.2 Competitive marketing support
Initially, we might predict that competitive marketing expenditures negatively affect
the time-to-peak-sales. Prins and Verhoef (2007) show that competitive advertising
reduces time to adoption. But competitive marketing efforts may also have a
category-building effect that enhances both own and competitors’ brand sales (Dubé
and Manchanda 2005; Fischer and Albers 2010) and may extend the time-to-peak-
sales. As a consequence, it is difficult to provide a clear prediction about the effect of
competitive marketing expenditures on time-to-peak-sales.
3.3.3 Number of competitors
The number of competitors in the market might also be relevant in explaining both
time-to and height-of-peak-sales. The market share theorem (Cooper and Nakanishi
1988) postulates that a brand’s market share is inversely related to the number of
competitors in a market. The brand looses in relative attractiveness. The loss in
attractiveness may have different sources. The memory-sequence effect (Alpert and
Kamins 1994) or the variety seeking phenomenon (McAlister and Pessemier 1982)
may explain the loss in attractiveness when more competitors are present in a
market. We expect that the number of competitors reduces both the time-to-peak-
sales and the height-of-peak-sales.
3.3.4 Price
In the empirical application, we use a sample of firms and brands from four
European countries (France, Germany, Italy, and the U.K.) during the period 1987–
1996. The systems of health insurance and price regulation in these countries explain
why pharmaceutical firms did not use price as a tactical marketing instrument in that
period. In France and Italy, prices are determined exogenously by the respective
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authorities. In principle, launch prices can be set freely in the U.K. and Germany.
Because drug expenses are typically reimbursed, demand is inelastic. As a result,
firms have no incentive to reduce the price over time. Since a subsequent increase of
the approved launch price would result in the loss of the reimbursement status, prices
are also not raised in later periods and thus stay rather constant. Hence, price plays
more or less the role of a cross-sectional control variable in this specific sample.
Note also that we do not observe generic price competition in the sample.
3.4 Summary
We provide a summary of the expected effects of our included drivers of time-to-
and height-of-peak-sales in Table 2. In this table, we also report the operationaliza-
tion of these variables, which we discuss in the next section in more detail. Finally,
we note that we do not include distribution as predictor in our model (Kremer et al.
2008; Manchanda et al. 2005), as drug distribution in Europe is highly regulated,
such that pharmacies are required by law to supply all approved prescription drugs.
4 Data
4.1 Data sources
We test our propositions using data from two prescription drug categories, calcium
channel blockers and ACE inhibitors. These categories differ in their therapeutic
principles for treating diseases such as hypertension or coronary heart disease. Data
collected by IMS Health are available on a quarterly basis for a time period of
10 years (1987–1996) in each country. During that period, calcium channel blockers
and ACE inhibitors represented the two largest (in monetary value) categories of
cardio-vascular therapy. They offered the most advanced therapy alternatives for the
treatment of hypertension, as an example, and substituted sales from established
older categories such as diuretics or beta blockers. Lipid modifying agents (e.g.,
Lipitor) and A-II-inhibitors (e.g., Cozaar), which lead today’s cardio-vascular drug
prescriptions, were only available at the very end of the observation period.
The data include normalized (across different application forms) unit sales
(transformed into daily dosages by a brand-specific dosage factor), daily dosage
price and marketing spending, including expenditures on detailing (>90% of total
spending), professional journal advertising and direct mailings. Sampling expendi-
tures and other below-the-line activities (e.g., dinner invitations for physicians) are
not covered. The data come from four European countries—France, Germany, Italy,
and the United Kingdom—and comprise 73 brands in eight product markets (2
categories × 4 countries). In addition, the data provide the month of product launch,
a quality measure for each NCE and marketing expenditures by competitors and
firms co-marketing the product, a frequently used method in this industry to enhance
the diffusion of a new drug among physicians.
Both categories experienced multiple brand entries during the study period. The
first calcium channel blocker was introduced in Germany in 1963 by Knoll, a
German company which has been acquired by Abbott. The first ACE inhibitor was
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introduced in the United States and other countries in 1981 by Bristol Myers-Squibb.
Additional countries followed quickly in both categories. Between 9 and 12 brands
entered the country markets in each category, with most entries occurring during our
observation period. Both categories experienced considerable growth in the 1980s,
which slowed down or even turned into negative growth by 1996. The categories are
comparable in their sales histories.
Even though the patent expired for a few early entrants in the calcium channel
blocker category in the 1980s, intense generic competition did not evolve during our
observed period. This is mainly due to the fact that cost containment issues did not
play an important role in prescription behavior at that time. The market share of the
few generic competitors is on average below 1%. In addition, we observe that all
innovative brands continued to grow after they lost patent protection, i.e. patent
expiry does not coincide with time-to-peak-sales.
Table 2 Variable definition and expected direction of effects
Variable Definition Expected Effect on …
Time-to-peak-
sales
Height-of-
peak-sales
Order of entry Count variable that counts the entry of NCEs into a
product market
− −
Quality Objective quality index based on evaluations of drug
quality in international meta-analytic review
reports (see Appendix B for details)
+/− +
Order of entry ×
quality
See above + N.A.
Control variables
Stock of own
marketing
expendituresa
MESt ¼
Pt
r¼0 1 ϕð ÞrExptr; +/− +
where
MESt = Stock of own marketing expenditures at the
end of quarter t
8 = (Estimated) quarterly depreciation rate
Expt = Own marketing expenditures in quarter t
See also Berndt et al. (1995, 102)
Stock of competitive
marketing
expenditures
Expenditures of all other brands (excluding co-
marketing partners) in a product market are
cumulated to produce competitive marketing
expenditures. The calculation of the stock follows
the approach as outlined under own marketing
expenditures.
+/− +/−
Number of
Competitors
Count variable that counts the number of NCEs that
have entered a product market in a specific quarter
− N.A.
N.A.—Not estimated due to collinearity issues or data limitations
a To estimate the depreciation rate 8, we replace the stock variables in the brand sales model (Eq. 3) by
quarterly marketing expenditures and add lagged sales to the predictor variables. The coefficient
associated with the lagged dependent variable measures the carryover-coefficient (1-8). To control for
brand heterogeneity in this model, we specify a random brand constant that follows a normal distribution
and estimate its mean and variance.
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4.2 Measurement and descriptive statistics
We adopt the slowdown measure by Golder and Tellis (2004) to determine each brand’s
time of peak sales and cross-validate this decision through visual inspections of the
time series. 45 brands out of 73 brands reach their peak sales during the 10-year
observation period. A few brand time series are left-truncated because they were
launched before the start of the observation period. Thus, we have an unbalanced panel
data set with 31 quarters per brand, on average, which we use to calibrate our model.
Our dataset shares a limitation with most previous studies on growth models. The
data series are censored to the right. Hence, in a very strict sense, we cannot be
absolutely sure that we observe the peak. It may just be a saddle phenomenon
(Goldenberg et al. 2002), although that has not been documented for pharmaceutical
brand sales so far. We therefore analyze the distribution of peak sales years and
times-to-peak sales. We find that more than 60% of peak sales occurred three years
before the end of the observation period or earlier. The distribution of peak-sales
years follows a normal distribution (p>.05). Additionally, we find that for 80% of
the brands time-to-peak-sales amounts to four years or longer. Hence, we have much
confidence that our data are representative of the peak sales phenomenon in the
analyzed categories. We also test the robustness of the results later when we change
the composition of the sample to eliminate left truncation issues, as an example.
In Table 3, we summarize information about the time-to- and height-of-peak-sales
for the 45 brands. The average time-to-peak-sales for calcium channel blockers is
higher because of the very early introduction of the pioneer in all countries that we
investigate. In several cases, early entrants continue to grow after later entrants
already have achieved their peak. We also note that the time of the category sales
peak does not necessarily coincide with the time when brand sales peak. Hence, the
time-to-peak in terms of category demand appears to be independent of the time-to-
peak in brand demand.
We provide means and standard deviations of other key variables for the 45
brands in Table 3. The height-of-peak-sales is slightly more than four times greater
than the average brand sales in both categories.
Time-to-peak-sales and height-of-peak-sales are correlated with .424. As expected,
the association is positive, i.e. a longer time-to-peak-sales helps accumulating sales
and achieving a higher level of peak sales. We also correlate our two focal measures
with the cumulative (unit) sales and approximated cumulative discounted cash flows
(DCF). The correlations of height-of-peak-sales with cumulative sales and discounted
cash flows are .981 and .935, respectively. Correlations are smaller but still sizeable
with respect to time-to-peak-sales: .470 (cumulative sales) and .336 (cumulative
DCF). In Section 7 we will further elaborate on the relationships of the peak-sales
metrics with cumulative sales and cumulative DCF.
The operationalization of the quality index deserves special attention. We adopt
an objective quality index based on international medical evaluation standards (for a
similar approach, see Venkataraman and Stremersch 2007). This index measures the
objective quality of each NCE along seven equally weighted dimensions that capture
the breadth of application, efficacy, convenience, and pharmaco-kinetic performance
of the drug. Specifically, the dimensions are the number of approved indications,
number of interactions, frequency of side effects, frequency of medication, protein
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absorption, plasma half-lifetime, and bioavailability (for details see Appendix B
including Table 8).
5 Econometric model and estimation
5.1 Brand-growth model
Bertalanffy (1957) proposes a generalized mathematical theory of growth that
encompasses many long-term growth models discussed in the marketing literature.
The idea behind that theory is that growth processes can be formalized by a general
differential equation that represents the antagonism of progress and decay. Diffusion
models such as the Bass (1969) model derive from that theory and have found wide
application in marketing. Several limitations of the Bass model, however, prevent its
use for our data. The model focuses on the category level and explains first-time
adoptions of a new product (Mahajan et al. 1990). We need to model sales at the
brand level that is composed of both adoptions and repeat purchases. We note that
there are a few extensions of the Bass model that apply to brand diffusion and
incorporate repeat purchases (e.g., Hahn et al. 1994; Krishnan et al. 2000). These
Table 3 Descriptive statistics (45 brands, 1,386 observations)
Variation over
timea
Calcium channel
blockers
ACE inhibitors
Mean Standard
deviation
Mean Standard
deviation
Time-to-peak-sales (in years) Time-invariant 9.69 8.10 6.37 3.74
Height-of-peak-sales (in mill. daily
dosages per quarter)
Time-invariant 81.02 90.71 60.11 56.28
Brand sales (in mill. daily dosages per
quarter)
Time-varying 19.29 20.08 14.00 12.75
Market share (in daily dosages) Time-varying .12 .14 .13 .14
Order of entry Time-invariant 4.71 2.77 4.43 2.68
Quality Time-invariant .98 .19 1.01 .09
Time in market (years) Time-varying 10.78 8.53 5.60 3.86
Price (in $ per daily dosage) Time-varying .52 .27 .72 .18
Number of competitors in product market Time-varying 8.37 2.33 7.81 2.36
Stock of own marketing expenditures per
quarter (in mill. $)
Time-varying 1.70 1.43 2.20 1.31
Stock of co-marketing expenditures per
quarter (in mill. $)b
Time-varying 1.31 1.28 1.36 .98
Stock of competitive marketing
expenditures per quarter (in mill. $)
Time-varying 19.51 8.83 20.67 9.24
a Note that time-varying variables that enter the time-to-process function (4) are used as time-invariant
variables, measured in the year when peak sales occurred
b For cases in which co-marketing agreements exist
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models, however, require accounting for competitor diffusion and repeat dynamics
that increase model complexity, especially if many brands are to be analyzed as in
our study. In addition, the Bass model assumes a growth process that is for the most
part symmetric around the time of peak sales.1 Previous research suggests that drug
sales follow an asymmetric life cycle (e.g., Bauer and Fischer 2000). A parametric
growth model that derives from Bertalanffy’s general theory but is not subject to
these limitations is Brockhoff’s (1967) model. It assumes an asymmetric growth path
that leads to a single peak in a brand’s lifetime. Consistent with this growth model,
we specify sales of brand i in (calendar) period t as follows2:
sit ¼ mi  LCTaiit  ebiLCTit  g Zit½ ; mi; ai; bi > 0; ð1Þ
where
sit Sales of brand i in period t
mi Brand-specific scaling constant
LCTit Elapsed time since market introduction of brand i in (calendar) period t
ai,bi Brand-specific growth parameters and
g[Zit] A multiplier shifting sales depending on the Z-vector of relevant predictors
of brand i in period t.
This model has several desirable properties. For example, if we differentiate Eq. 1
with respect to LCT and set the expression equal to 0, we obtain an expression for
the time-to-peak-sales, y i ¼ aibi, and thus
ai ¼ biy i ð2Þ
5.2 Brand sales model
Following Ainslie et al. (2005), we insert Eq. 2 into (1). We introduce k for category,
l for country, specify the variables in Z explicitly, and take the logarithm of sales to
derive an equation that is linear in response parameters. We then arrive at:
ln sklit ¼ lnmkli þ bkliykli ln LCTklit  bkliLCTklit þ b1 lnOEkli þ b2 lnQkli þ b3 lnPRCklit
þg1kli lnMESklit þ g2kli lnComMESklit þ g3kli lnCoMESklit þ
PH1
h¼1 dhlSDhlt
þnk þ t l þ wkl þ uklit;
with nk i:i:d: N 0; s2n
 
; t l i:i:d: N 0; s2t
 
;wkl i:i:d: N 0; s2w
 
; uklit i:i:d: N 0; s2u
 
;
mkli ¼ mþ hkli and hkli i:i:d: Nð0; s2hÞ; bkli ¼ bþ ukli and ukli i:i:d: N 0; s2u
 
;
ykli ¼ y þ mkli and mkli i:i:d: Nð0; s2mÞ; gkli ¼ gþlkli and lkli i:i:d: N 0;Λð Þ;
ð3Þ
where:
OEkli Order of entry of brand i in category k and country l
Qkli Quality of brand i relative to the average in category k and country l
1 Let tPeak be the period of peak sales. Then, sales evolves symmetrically within the interval [tPeak-2tPeak,
tPeak+2tPeak] (Mahajan et al. 1990).
2 The corresponding Bertalanffy differential equation is dsidLCTi ¼ ai 1LCTi si  bisi; with ai; bi > 0.
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PRCklit Price of brand i in category k, country l, and period t
MESklit Stock of own marketing expenditures of brand i in category k,
country l, and period t
ComMESklit Stock of marketing expenditures by brand i′s competitors
(excluding co-marketing partners) in category k, country l, and
period t
CoMESklit Stock of marketing expenditures by pharmaceutical companies
that co-market brand i in category k, country l, and period t
SDhlt Seasonal dummy variable for quarter h in country l and period t
m,= ,b,β,g,δ (Unobserved) parameter vectors
v,t,w, u,σ² Error terms and error variances
k 1, K=2 (number of categories)
l 1, 2, .., L=4 (number of countries)
i 1, 2, …, Ikl (number of brands per category and country)
t 1, 2, …, Ti (number of observation periods per brand); and
h 1, 2, ., H=4 (number of quarters).
Recall that a product market is defined as category by country. The terms ηkli, υkli,
μkli, and lkli denote brand-specific deviations of heterogeneous parameters from their
mean ðm; b;y; and gÞ across product markets and brands, assumed to be drawn from
a normal distribution with 0 mean and constant variance. In this way, we account for
heterogeneous effects that facilitate the pooling of the cross-sectional and time-series
data. We do not model β1 and β2 as heterogeneous because these parameters are
associated with time-independent variables. Although in theory, it is possible to
identify heterogeneous parameters from purely cross-sectional information, it remains
a challenging task in real data sets (Bodapati and Gupta 2004). This logic also applies
to β3, the parameter associated with price. Although price is fundamentally a time-
varying quantity, we observe almost no time variation in our data supporting our view
that it was not used as a marketing instrument by firms. Here, we treat price as a
cross-sectional control variable. The model also includes a brand-specific scaling
constant (mkli) that controls for unobserved brand-specific effects, such as brand
equity, that are assumed to be randomly distributed across brands.
We followBerndt et al.’s (1995) approach for measuring the stock of pharmaceutical
marketing expenditures, and find a quarterly carryover coefficient of .540 (see Table 2
for more details). We test whether the carryover coefficient differs for the two product
categories but find no significant differences. By including marketing stock variables,
we account for sales dynamics that are typical for new drugs due to inertia and
diffusion effects. The stock of competitive marketing expenditures reflects the impact
of competitors’ marketing campaigns on own brand sales. We include the stock of co-
marketing expenditures to account for the impact of co-marketing deals between
pharmaceutical firms. The brand sales model accommodates possible seasonal
fluctuations in drug demand by country according to quarterly dummy variables.
Finally, the model shows a nested, multilevel error structure which consists of error
components that are category-specific, νk, country-specific, t l, and product-market-
specific, wkl. We assume these errors and the idiosyncratic error, uklit, to be
uncorrelated. As a result, the error variance is Var nk þ t l þ wkl þ uklitð Þ ¼
s2n þ s2t þ s2w þ s2u. With this error structure, we account for differences in market
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size between categories, countries, and product markets. In addition, this specification
implies that errors are contemporaneously correlated across categories within a
country, across countries within a category, and across brands within a product market.
5.3 Time-to-peak-sales model
The brand sales model (Eq. 3) includes the time-to-peak-sales, = kli, as an unobserved
heterogeneous parameter that can be decomposed into a mean and a random
component. We extend this specification and allow the mean to be shifted by the
following cross-sectional variables:
ykli ¼ a0 þ a1OEkli þ a2Qkli þ a3OEkli  Qkli þ a4 lnMESkli;tPEAKi
þ a5 lnComMESkli;tPEAKi þ a6 lnNCkli;tPEAKi þ zkli; ð4Þ
where tPEAKi denotes the calendar year in which a brand achieved its peak sales, NC
denotes the number of competitors in a product market, K is an i.i.d. error term
uncorrelated with the error terms of Eq. 3, and all other terms are defined as
previously. We take the log of the number of competitors, and of own and competitive
marketing stock to account for diminishing returns, measured at the time the brand
reaches its peak sales. Order of entry and quality, which are time-invariant, get
measured at the time of launch. Note that tPEAKi measures calendar time that is
unrelated to = kli, a duration variable (correlation coefficient=−.171, p>.10). Hence,
there are no endogeneity concerns arising from time of measurement.
5.4 Estimation
Equations 3 and 4 establish a multi-level regression model. We estimate the model
using the simulated maximum likelihood technique that was also used by Fok and
Franses (2007). Under the usual regularity conditions, the estimator is consistent and
asymptotically normal distributed.
5.5 Elasticities
When we differentiate Eq. 4 with respect to the predictors of interest, we obtain the
marginal time-to-peak-sales effect of that variable, which we can easily transform into
an elasticity-based measure. To derive the height-of-peak-sales effects, we substitute
Eq. 4 into 3 and differentiate the expression with respect to the predictor variable of
interest (see Appendix C for details). The formal expressions for the time-to- and
height-of-peak-sales elasticities appear in Table 4. Because order of entry and number
of competitors are non-continuous variables, we must interpret their elasticity with
care. Before we discuss the estimation outcomes we elaborate on endogeneity issues.
5.6 Endogeneity issues
Our model includes several strategic variables that may be endogenous. For
example, because pharmaceutical firms decide about the timing of product launch,
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product quality, and the level of marketing investment taking (past) sales into
account, failing to account for endogeneity can lead to biased or inconsistent
parameter estimates (Franses 2005). We executed Wu-tests to assess whether the
exogeneity assumption is violated for our included variables (Greene 2004). These
tests show that (1) order of entry (OE), (2) quality (Q), (3) long-term marketing
investment until time-to-peak-sales ðMEStPEAK Þ, and (4) the number of competitors
ðNCtPEAK Þ are indeed endogenous (p<.01). The Wu-test shows that the exogeneity
assumption with respect to competitive marketing expenditures (p>.05) and co-
marketing expenditures (p>.05) is not violated. Hence, we estimate a reduced-form
model and employ instrumental variables estimation with exogenous information
that identifies the firm’s strategic variables (Franses 2005) for the four variables OE,
Q, MEStPEAK and NCtPEAK . For details on this procedure, we refer to Appendix D.
One alternative way to deal with endogeneity issues would be to model firm
interactions in an equilibrium framework (e.g., Chintagunta et al. 2006). Given the
long time horizon of 10–12 years required to develop a new drug and the
uncertainties associated with the outcomes of clinical trials and the approval process,
an appropriate model would feature the solution to a dynamic stochastic game
among 8 to 10 firms that decide about entry timing, quality, and long-term marketing
investments. Such a model is beyond the scope of this paper.
6 Estimation results
6.1 Model fit
We present the estimation results for the brand-sales model applied to the eight
product markets in Table 5. Model fit is very good. To assess the in-sample and out-
of-sample fit, we exclude the last four quarters of year 1996 from estimation.
Squared correlation between predicted and actual values of the dependent variable
amount to .969 in the estimation sample (1,206 observations) and .941 in the hold-
Table 4 Definition of peak-sales effects (elasticities)
Relative change in …
Due to relative change in … Time-to-peak-sales Height-of-peak-sales
Order of entry
a1þa3Qð ÞOE
LCT
PEAK b a1 þ a3Q
 
ln LCT
PEAK
OE þ b1
Quality
a2þa3OEð ÞQ
LCT
PEAK b a2 þ a3OE
 
ln LCT
PEAK
Qþ b2
Stock of own marketing expenditures a4
LCT
PEAK ba4 lnLCT
PEAK þ g1
Stock of competitive marketing expenditures a5
LCT
PEAK ba5 lnLCT
PEAK þ g2
Number of competitors a6
LCT
PEAK –
A bar over the variable indicates the mean. Order of entry and number of competitors are treated as
continuous variables to derive the elasticity measure. See Appendix C for details
Drivers of peak sales for pharmaceutical brands 445
out sample (180 observations).3 Table 5 includes the estimated means and standard
deviations of the distributions for heterogeneous parameters. All estimates for which
we explicitly predict the direction of the effect show the expected sign.
We also check for serial correlation in the error term but do not find evidence for
it. The autocorrelation coefficient is .048 (p=.605). Note that sales dynamics are
3 The model fit may appear unusually high for a panel data set. It reflects, however, the extensive selection
of predictors and specification of brand heterogeneity in the constant and slope parameters which finally
leads to a model that adapts to the specifics of each individual brand time-series. Note that R² for a simple
OLS model with homogenous coefficients already amounts to .808 reflecting the strong explanatory
power of the selected predictor variables.
Table 5 Estimation results for the brand sales model (Eqs. 3 and 4)
Parameter
estimate
Estimated SD of
parameter distribution
Scaling constant ln m 6.31 (.164) .000 (.009) NS
Time-to-peak-sales process function
Constant b × α0 2.44 (.219)
Order of entrya b × α1 −.373 (.024)
Qualitya b × α2 −1.83 (.151)
Order of entry × qualitya b × α3 .354 (.021)
Log(stock of own marketing expenditures)a b × α4 .077 (.016)
Log(stock of competitive marketing expenditures) b × α5 .020 (.015)
NS
Log(no. of competitors within product market)a b × α6 −.184 (.033)
Error standard deviation σμ .145 (.151)
NS
Brand sales function
Elapsed time since launch (growth constant) b .096 (.004) .119 (.004)
Log(order of entry)a β1 −.589 (.030)
Log(quality)a β2 2.49 (.235)
Log(price) β3 −.321 (.022)
Log(stock of own marketing expenditures) γ1 .346 (.007) .087 (.002)
Log(stock of competitive marketing expenditures) γ2 −.155 (.019) .054 (.001)
Log(stock of co-marketing expenditures) γ3 .012 (.005) .051 (.003)
Category-specific error component
(standard deviation)
sn .013 (.012)
NS
Country-specific error component
(standard deviation)
st .002 (.010)
NS
Product-market-specific error component
(standard deviation)
sw .010 (.009)
NS
Log Likelihood −495.10
No. of brands 45
No. of observations 1,386
Standard errors in parentheses. Estimated seasonal effects are not reported and may be obtained from the
authors. NS = not significant (p>.05)
a Instrumental variables used.
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implicit to the definition of our stock variables (see Table 2 again). In addition, we
explicitly model growth dynamics in Eq. 1.
6.2 Model comparison
In the existing literature, there are several competing sales growth models including
diffusion models and parametric growth models. We compare the selected model
with alternative parametric growth models that can be derived from Bertalanffy’s
growth theory. Specifically, we consider the model used by Shankar et al. (1999) for
pharmaceuticals and a model that represents a symmetric sales evolution and is
comparable to the Bass model. According to the Bayesian Information Criterion, the
model turned out to be inferior (−1,455.8proposed vs. −1,592.0symmetric vs.
−1,594.5Shankar et al.). The squared correlations of predicted and actual values of
the citerion variables in the estimation and holdout samples also appear to be lower
(.900/.886 for the symmetric model and .961/.936 for the Shankar et. al. model).
Hence, we conclude that for our data, Brockhoff’s model best represents the brand
growth process.4
Another alternative model is the one suggested by Fok and Franses (2007), which
represents an extension of the Bass model (see also Boswijk and Franses 2005). As
noted earlier, their model studies time-to-peak-citations and peak citations.
Specifically, they propose a multi-level regression model to measure determinants
of these two citation metrics. Our model is similar to theirs as we also propose a
multi-level regression model using the same estimation technique (simulated
maximum likelihood). Our model is, however, more parsimonious as we only have
one second-level equation, while their approach requires estimating four of such
equations. Importantly, the Fok and Franses diffusion model is specified in terms of
cumulated brands sales, which we do not observe for brands earlier than the start of
our observation period. Although we cannot use the full sample, we calibrate and
compare the extended Bass model with our suggested model in a reduced sample of
26 brands (635 observations). Since both models are calibrated on different sets of
criterion and predictor variables a direct comparison in terms of fit measures is not
possible. We therefore apply the Davidson/McKinnon-test (see e.g., Greene 2004).
The idea of this test is to use the predicted values of the alternative model as an
additional predictor adding potentially relevant new information to the focal model.
The test is inconclusive for our data, i.e. the two models are not superior to each
other. The advantage of our proposed model is, however, that it can be applied to the
full sample.
6.3 Time-to-peak-sales process function
We find a negative main effect of order of entry on time-to-peak-sales (α1=−.373,
p<.05), indicating that later entrants achieve their peak sales earlier, consistent with
our expectation. This result also complements previous findings regarding the
4 We also checked whether the brand time-series show multiple peaks by visual inspection. The
phenomenon occurs at the quarterly level due to short-term sales fluctuations. Aggregated to the annual
level, sales evolution appears much smoother indicating a single peak.
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impact of order of entry on brand growth (Kalyanaram and Urban 1992). The main
effect of quality is negative, which implies that a quality improvement reduces time-
to-peak-sales (α2=−1.83, p<.05); we proposed arguments in favor of both
directions. The interaction effect between quality and order of entry, however, is
positive (α3=.354, p<.05). That is, a higher quality limits the negative effect of
order of entry on time-to-peak-sales. The total effect of a change in entry order
(quality) for a brand, given a certain quality (entry order position), can be assessed
by calculating the elasticities of Table 4 (see Section 6.5.1).
We find a positive impact of the stock of own marketing expenditures on time-to-
peak-sales (α4=.077, p<.05). The effect of the stock of competitive marketing
expenditures is not significant (α5=.020, p>.05). Consistent with our expectation,
we find a negative time-to-peak-sales effect for the number of competitors within the
market (α6=−.184, p<.05).
6.4 Brand sales level
Consistent with prior research, we find a significant negative direct impact of order
of entry on sales (β1=−.589, p<.05). The estimated value is close to its generalized
value of −.50 (Kalyanaram et al. 1995). Quality has a strong and positive influence
on sales (β2=2.49, p<.05), in support of our expectation. For price, we find a
negative but inelastic coefficient, which confirms our expectation (β3=−.321,
p<.05). Recall that in our dataset price mainly varies across cross sections. We also
find a positive impact of the stock of own marketing expenditures on sales (γ1=.346,
p<.05) but a negative effect of the stock of competitive marketing expenditures
(γ2=−.155, p<.05). Finally, the impact of the stock of co-marketing expenditures on
sales is positive and significant (γ3=.012, p<.05). These marketing expenditure
variable estimates refer to average effects. The large standard deviation associated
with the effect of co-marketing activities reveals that some brands suffer from
cannibalization effects (i.e., γ3kli<0 for some i).
6.5 Estimated peak-sales elasticities
6.5.1 Time-to-peak-sales elasticities
Following Table 4, we compute peak-sales effects in terms of elasticities to make
results comparable across variables. Recall that these estimates are not directly
available from the parameter estimates of the brand sales model in Table 5 and may
differ across brands. We report the average effect over all brands in our sample. As
we show in Table 6, the elasticities of time-to-peak-sales with respect to order of
entry (= −.126, p<.05) and quality (= −.264, p<.05) are negative. That is, for the
average brand, an increase in these variables reduces the time until it reaches peak
sales. The elasticity of quality is greatest in terms of absolute value; this result is
based on the average order-of-entry position in our data, which is between 4 and 5.
The stock of own marketing expenditures depicts a positive time-to-peak-sales
elasticity (=.099, p<.05). Hence, for the average brand, marketing investments
prolong the time span until peak sales. Finally, we find a significant negative
elasticity of time-to-peak-sales associated with the number of competitors in the
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market (= −.235, p<.05). The elasticity of the stock of competitive marketing
expenditures is not significant (= .025, p>.05).
6.5.2 Height-of-peak-sales elasticities
Quality elasticity is greatest in absolute value (= 2.06, p<.05), followed by the
negative order-of-entry elasticity (= −.796, p<.05) and the positive elasticity with
respect to the stock of own marketing expenditures (= .507, p<.05). Note, however,
that the elasticity of the actual expenditure level, which is required to achieve a
certain stock level, is lower. Multiplying the stock elasticity by the estimated
depreciation factor bϕ ¼ :460, we obtain a value of .233. Competitive marketing
activity has the smallest effect on height-of-peak-sales but is nevertheless substantial
(= −.114, p<.05). In summary, quality, order of entry, and own marketing
expenditures emerge as significant drivers of the height-of-peak-sales, underlining
the importance of these strategic variables in the pharmaceutical industry.
6.6 Robustness
We perform several analyses to check the robustness of our findings. First, we
investigate the robustness of the results against collinear influences, focusing on
order of entry, quality, and their interaction. To determine whether multicollinearity
has a destabilizing influence on the parameter estimates, we regress OOE, Q, and
OOE×Q on either OOE or Q or both of them. The residuals from these regressions
alternatively might be used in model estimation (Hill and Adkins 2003). The
consistent and collinearity-free estimates confirm the results reported in Table 5.
Note that we need to exclude the number of competitors and the interaction of order
of entry with quality from the brand sales equation due to collinearity issues. Using
the above described procedure, we obtain collinearity-free estimates for these
variables that are consistent with our expectation.
Second, we check whether our results may be driven by the composition of the
sample by applying the model to five new samples. The first sample consists only of
brands launched during our observation period, which eliminates the issue of left
Table 6 Estimated peak-sales elasticities (evaluated at sample means)
Relative Change in …
Due to Relative Change in … Time-to-peak-sales Height-of-peak-sales
Order of entry −.126 (.025) −.796 (.284)
Quality −.264 (.116) 2.06 (.305)
Stock of own marketing expenditures .099 (.022) .507 (.031)
Stock of competitive marketing expenditures .025 (.019) NS −.114 (.031)
Number of competitors −.235 (.036) N.A.
N.A.—Not estimated due to collinearity issues or data limitations
Approximated standard errors in parentheses. Note that the effects for order of entry and quality are total
effects and account for the interaction effect. NS = not significant (p>.05)
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truncation. In the second sample, we eliminate the pioneer brand to control for a
possible sample bias that might arise from the long lead time of the pioneer. In the
third and fourth samples, we apply more conservative rules to classify brands that
have passed their peak sales, leading to reduced sizes of 40 and 36 brands,
respectively. The last sample contains all 73 brands, including brands that have not
achieved peak sales yet. In this case, we must exclude the stock of own and
competitive marketing expenditures from the process function in Eq. 4 because we
do not observe these quantities for all brands. The results do not change
substantially, which underlines the robustness of our findings.
Third, we regress observed time-to- and height-of-peak-sales on our focal drivers
in a cross-sectional regression that covers the 45 brands of our sample (see also
Section 7 and Table 7). We find significant effects for several drivers, consistent with
our results from the full model. Note that these cross-sectional regressions test the
effects on peak-sales metrics without making any assumptions about the functional
form of the growth model, which provides evidence that our results are not driven by
the type of growth model.
Fourth, we check whether the model improves if we include quality dimensions
separately or use an unbalanced weighting scheme for the composite measure. We
do not find evidence for model improvement. We also check to what extent results
change if we define quality as a time-varying measure by dividing the quality index
of a brand by the average quality of all competitors in the market. Results are very
stable. This is because quality is by large a cross-sectional phenomenon in our data.
Cross-sectional variation accounts for 92% in total variance for the time-varying
quality measure.
7 Cross-sectional analysis of new product performance
A basic premise of this article is that the two suggested peak sales metrics are highly
relevant for explaining new product success in the pharmaceutical industry. In this
section, we test whether this premise holds for the 45 brands in our sample. For that
purpose, we regress cumulative brand (unit) sales and cumulative discounted brand
cash flows (DCF) as measures of new product performance on the two peak-sales
metrics and their drivers. In addition, we analyze the drivers of time-to- and height-
of-peak-sales in this cross-sectional setting.
We subtract the marketing expenditures from revenues and discount them by a
quarterly rate of 3% (≈12.5% per annum) to obtain discounted cash flows (DCF).
Marginal costs for new pharmaceuticals are usually very low accounting for only 10-
15% of revenues. They do not vary much across brands and time. The most important
sources of variation are revenues and marketing expenditures which are available to us.
Table 7 shows the results of the four cross-sectional regressions. Standard errors are
White-corrected to account for cross-sectional heteroskedasticity (Greene 2004) and
endogenous variables are instrumented as reported earlier. We discuss first results for
the two peak-sales metrics. Specifications are consistent with Eqs. 3 and 4. By
definition, the dynamic brand sales function produces the height-of-peak-sales by
including time-to-peak-sales into the vector of arguments (see Appendix C again).
Hence, it is part of the predictor set for the height-of-peak-sales regression in Table 7.
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Overall, the results strongly support the findings of Table 5. We note, however,
that most of the coefficients related to the time-to-peak-sales drivers do not achieve
significance. The small sample size of 45 observations together with five
instrumented predictors suggests that the statistical power is not very high. The
situation is less critical for height-of-peak-sales as dependent variable. Here, we find
a significant positive influence of time-to-peak-sales (elasticity of .736). Note that
this finding cannot be driven by the type of growth function because we do not
specify any growth function.
The last two columns of Table 7 show the results with respect to cumulative brand
sales and cumulative DCF. The findings impressively suggest that both peak-sales
metrics are highly relevant predictors of new product success. R² is as high as .965
for cumulative brand sales and .881 for cumulative DCF. Moreover, we find that
none of the driver variables such as order of entry, quality, etc. add explanatory
power above and beyond the peak sales metrics. Hence, we find strong evidence for
our basic premise of the relevance of peak-sales metrics.
While time-to-peak-sales has a positive direct and indirect (via height-of-peak-
sales) impact on cumulative brand sales it should also have an opposite effect on
cumulative DCF due to time discounting. To separate these effects we include the
log of time-to-peak-sales in that regression and indeed find a non-monotonic,
inverted U-relationship. Based on the estimates, the turning point occurs only after
several years suggesting that the negative discounting effect is not large enough to
offset the positive impact of time-to-peak-sales on new product performance.
8 Conclusions, limitations, and future research
We suggest two new metrics of new product performance: time-to-peak-sales and
height-of-peak-sales. Our empirical analysis provides strong evidence for the power of
these metrics to explain the performance of new drugs. By developing a brand sales
growth model, we simultaneously model the effect of order of entry, quality, and
control variables on time-to- and height-of-peak-sales. The estimation results provide
interesting insights. Order of entry impacts both time-to- and height-of-peak-sales.
More specifically, early entrants achieve peak-sales later, and they have higher peak-
sales levels. Quality is also an important driver of peak-sales. High-quality brands
achieve peak sales earlier. In addition, higher quality is associated with a higher level
of peak sales. We also study the moderating effect of quality on the order-of-entry
effect on time-to-peak-sales. Our results indicate that late entrants have longer
expected time-to-peak-sales when they introduce a brand with high quality. Or stated
differently, quality limits the negative effect of order of entry on time-to-peak-sales.
One explanation for this finding is that due to the higher quality the late entrant is able
to attract customers from early entrants increasing its adopter potential which in turn
requires more time to be penetrated resulting in a longer time-to-peak-sales. Together
these findings thus support the available notions in the literature that both order of
entry and quality are important drivers of new product success.
Our results also shed some further light on the discussion on which decision
variable is more important, order of entry or quality (Tellis and Johnson 2007). Our
results suggest that both variables are important, as they offer the largest elasticities for
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time-to- and height-of-peak-sales compared to other variables such as competitive
entries. However, peak-sales elasticities with respect to quality are even higher than for
order of entry. This observation complements the finding on the dominant role of
quality for firm value (Tellis and Johnson 2007). However, more research is warranted
to study the important trade-off between quality and order of entry.
Our study is also subject to limitations. The estimation results hold for two
(related) categories of pharmaceuticals. It would be interesting to extend the analysis
to other pharmaceutical categories and even other industries. In addition, we cannot
generalize our findings to alternative growth model specifications. A regression of
observed times-to-peak sales on our focal variables, which is not subject to specific
assumptions about the growth model, finds similar results. Hence, we have much
confidence that our results do not suffer from this limitation. Future research,
however, should investigate to what extent peak-sales metrics are influenced by
specific assumptions about the growth model.
Although we analyze the effects of several important variables such as order of
entry, quality, and marketing support, we do not claim they are the only important
predictors of the time-to- and height-of-peak-sales. More research should investigate
the role of other variables. The level of retail support for over-the-counter drugs
might be an excellent candidate in this respect. If more data were available
researchers could also extend the analysis to cover total brand lifetime. Finally, in
this study we specifically focused on peak-sales as a key metric at the brand level.
Studying other metrics goes beyond the focus of our investigation.
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Appendix A
Sales volatility and growth
Assume we observe product sales s from launch until t=T *, the period when sales
reach their maximum level. Assume further that sales evolve at an annual compound
sales growth rate g. Denoting the sales level in the launch year (t=0) with k, we can
describe sales evolution in terms of the starting level k and the annual compound
growth rate g. Cumulative sales at t=T * are given by
XT »
t¼0 st ¼
XT »
t¼0 k 1þ gð Þ
t;with k  0 and g  0: ðA:1Þ
Drivers of peak sales for pharmaceutical brands 453
Note that the mean E[st]=μ of the sales time-series, s0, s1, …, st, …, sT*, is
defined as
m ¼ 1
1þ T »
X
t
k 1þ gð Þt ðA:2Þ
Intuitively, the average sales level should be higher the higher the growth rate,
which can be shown by differentiating (A.2) with respect to g
dm
dg
¼ 1
1þ g k
1
1þ T »
X
t
t 1þ gð Þt > : ðA:3Þ
We can demonstrate that the variance in sales as a measure of volatility increases
in the growth rate. Let us decompose the variance of sales into
Var stð Þ ¼ E s2t
  m2 ðA:4Þ
Because Var (st)>0, it follows E s2t
 
> m2 and we can write for (A.4)
Var stð Þ ¼ rm2  m2; with r ¼
E s2t
 
m2
ðA:5Þ
Differentiating (A.5) with respect to g gives
dVar stð Þ
dg
¼ 2 r  1ð Þ dm
dg
ðA:6Þ
Since r > 1 and dμ/dg > 0, expression (A.6) is always greater than zero. Hence, the
larger the sales growth is the larger the sales volatility. If the same level of peak sales
is reached in shorter time, the volatility in sales must increase.
Appendix B
Definition of the quality measure
Two healthcare professionals who work in the pharmaceutical industry compiled the
data for each quality dimension for each drug from published international drug
review reports. These reports are like meta-analysis reports, in that they collect
combined evidence about the seven quality dimensions from studies published
primarily in academic journals and summarize them. The performance measure of a
drug uses different units for different dimensions: percentage (bioavailability, protein
absorption), hours (plasma half-lifetime), and frequency (average occurrence of side
effects, number of interactions, number of indications, dosage per day). Side effects,
interactions, and required dosage are reverse coded. The efficacy dimensions,
bioavailability, protein absorption, and plasma half-time relate positively to efficacy,
so there are no code reversals for these dimensions. The same applies to the number
of indications.
The performance of a drug on each quality dimension is transformed into a value
that represents its performance relative to the mean performance of all drugs in its
category on that dimension. For each drug, the relative values of quality are
454 M. Fischer et al.
aggregated across all dimensions to provide an overall quality index for that drug.
The final results are cross-validated by two leading doctors at a reputed university
hospital. Table 8 provides the exact measurement approach for each dimension.
Let X 1;X 2;X 3;X 4;X
0
5;X
0
6; andX
0
7 denote the mean across all drugs within a
category. The quality measure is then defined by taking the average of the relative drug
performance across the seven dimensions, i.e. Q ¼ 17 X1X 1 þ
X2
X 2
þ X3
X 3
þ X4
X 4
þ X
0
5
X
0
5
þ X
0
6
X
0
6
þ X
0
7
X
0
7
 
.
Appendix C
Derivation of peak-sales elasticities
The time-to-peak-sales and height-of-peak-sales effects in Table 4 are derived
according to the method described below. Without loss of generality, we demonstrate
the derivation with respect to order of entry. We calculate the effect for the average
brand in our sample; mean values are indicated with a bar over the variable.
(1) Time-to-peak-sales elasticity
For ease of exposition, we omit the brand, category, country, and time subscripts.
We define the time-to-peak-sales effect of order of entry as the change in time-to-
peak-sales due to a change in the order of entry. We treat order of entry as a
continuous variable. Hence, we take the first derivative of Eq. 4 with respect to OE:
@y
@OE
¼ a1 þ a3Q ðC:1Þ
To express Eq. C.1 in terms of an elasticity measure, "y;OE , we multiply it by
OE y= :
"y;OE ¼
a1 þ a3Q
 
OE
y
ðC:2Þ
Table 8 Measurement of quality dimensions
Quality dimension Measurement Notation Transformation
Bioavailability In % (100% = full bioavailability) X1 No
transformation
Protein absorption In % (100% = full absorption) X2 No
transformation
Plasma half-lifetime In hours X3 No
transformation
Number of indications Counts the number of approved indications
for the drug
X4 No
transformation
Frequency of side
effects
Average occurrence of side effects in % X5 X
0
5 ¼ 1 X5=
Number of interactions Counts the number of dangerous drug interactions X6 X
0
6 ¼ 1 X6=
Dosage Counts the number of intakes of medicine per day X7 X
0
7 ¼ 1 X7=
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Note that we do not estimate the parameters α1 and α3 directly but rather estimate
their product with the average growth parameter (after substituting Eq. 4 into 3).
Define c1 ¼ ba1 and c3 ¼ ba3. Because we estimate c1, c3, and b, we can apply the
delta method to obtain the standard error for expression (C.2):
SE "y;OE
  ¼
1
b
2 Var c1ð Þ þ
c1 þ c3Q
 2
b
4 Var b
 þ Q2
b
2 Var c3ð Þ
 2 c1 þ c3Q
 
b
3 Cov c1; b
  2Q c1 þ c3Q 
b
3 Cov c3; b
 þ 2Q
b
2 Cov c1; c3ð Þ
26666664
37777775
1 2=
OE
y
 
ðC:3Þ
(2) Height-of-peak-sales elasticity
Define LCT== in Eq. 3, substitute Eq. 4 into this expression, and differentiate
with respect to OE:
1
sPEAK
@sPEAK
@OE ¼ b @y@OE lny þ
by @y@OE
LCT
PEAK  b @y@OE þ b1OE
¼ b @y@OE lny þ b1OE :
ðC:4Þ
Substitute Eq. C.1 into C.4 and multiply by sPEAK to obtain the marginal effect:
@sPEAK
@OE
¼ b a1 þ a3Q
 
lny þ b1
OE
 	
sPEAK ðC:5Þ
Multiplying Eq. C.5 by OE sPEAK


gives the elasticity measure in Table 4:
"sPEAK ;OE ¼ b a1 þ a3Q
 
lnyOE þ b1 ðC:6Þ
Given that ba1 ¼ c1; ba3 ¼ c3; b, and β1 are directly estimated, Eq. C.6 is a linear
combination of random variables, and a standard error estimate is readily available:
SE "sPEAK ;OE
  ¼ Var c1ð Þ þ Q2Var c3ð Þh i OE lny 2 þ 2QOE lnyCov c1; c3ð Þ
þVar b1ð Þ þ 2OE lnyCov c1; b1ð Þ þ 2QOE lnyCov c3; b1ð Þ
( )1 2=
ðC:7Þ
Appendix D
Procedure of instrumental variables estimation
Our instrumental variables estimation approach follows a multi-stage procedure. In
the following, we describe for each instrumented variable how we proceed to obtain
the respective instrumental variable that is used in the final estimation step whose
results are reported in Table 5.
Quality We regress the quality variable on firm dummies. Specifically, we regress
the quality ratings of 73 brands on 10 firm dummies. R² amounts to .305. The
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predicted values of this regression are used as instrumental variable for quality and
log(quality) (after log transformation).
Order of entry We regress the order-of-entry variable on the variables listed in
Table 9. To account for the ordinal nature of the dependent variable, we use an ordered
probit model. Quality and market share are, however, themselves endogenous and
need to be instrumented for use in the order-of-entry equation. We have already
reported on the instruments used for quality. For market share, we regress the log of
market share on brand dummies, the log of price, and the log of the stocks of own
marketing expenditures, competitive marketing expenditures, and co-marketing
expenditures. R² amounts to .850. We take the antilog of the predicted value in the
last period observed for each brand as instrumental variable for the (expected) long-
term market share. Table 9 shows the estimation results for the final order-of-entry
regression. From this regression, we obtain the predicted order of entry for each brand
which is further used as instrumental variable in the final estimation equation. Squared
rank correlation (pseudo R²) of predicted with actual values amounts to .464.
Long-term marketing expenditures We regress the stock of own marketing
expenditures at the time of peak sales on the marketing expenditures of the fourth
quarter of the preceding year. R² amounts to .607. The log of predicted values of this
regression are used as observations for an instrumental variable for log(long-term
marketing expenditures).
Number of competitors We regress the log of the number of competitors in a category
on the log of the average number of competitors in this category in the remaining three
countries. R² amounts to .781. The predicted values of this regression are used as
observations for the instrumental variable in the final estimation step.
Table 9 Estimation results for order-of-entry equation (ordered probit model)
Expected sign Coefficient Standard Error
Constant −1.54 (1.17) NS
(Expected) long-term market sharea − −7.30 (1.37)
Qualitya + 2.73 (.681)
Time taken to obtain drug approval + .242 (.047)
Entry in home country − −.160 (.470) NS
Net income prior to market entry − −4.6×10−4 (1.3×10−4)
Firm size (no. of employees) prior to market entry − .003 (.003) NS
Availability of co-marketing partner − .107 (.266) NS
Speed of international market rollout − −.004 (.123) NS
Log Likelihood −132.81
McFadden’s R²/Pseudo R² (squared rank correlation) .218/.464
No. of brands (observations) 73
NS = not significant (p>.05). Details on variable operationalization may be obtained from the authors on
request. Full sample of 73 brands used to explain order of entry
a Instrumental variables used
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